English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background  This study evaluated the effectiveness and safety of grapiprant for treatment of pain in dogs with osteoarthritis ( OA ).    Hypothesis/Objectives  Grapiprant will relieve pain as measured by the owner's and veterinarian's evaluation of pain in dogs with  OA . Another objective was evaluation of the safety of grapiprant.    Animals  Two hundred and eighty‐five client‐owned dogs with  OA  were enrolled and treated with grapiprant or placebo with 262 cases (N = 131 in each group) evaluable for the effectiveness analysis.    Methods  In this prospective, randomized, masked, placebo‐controlled study dogs were treated daily with grapiprant (2 mg/kg) per OS or placebo. Owners completed an evaluation using the Canine Brief Pain Inventory ( CBPI ) on days 0, 7, 14, 21, and 28. Success was defined as improvement in the  CBPI . Veterinary assessments were made on screening and days 14 and 28. Safety was evaluated by physical examination, evaluation of clinical pathology results, and owner observations.    Results  Grapiprant treatment improved pain compared to placebo on day 28 (48.1 and 31.3% treatment successes respectively;  P  = .0315). The pain interference score (PIS) and pain severity score (PSS) improved in the grapiprant group compared to placebo ( P  = .0029 and 0.0022, respectively). Veterinary assessments were significantly better in the grapiprant‐treated dogs ( P  = .0086). Grapiprant generally was well tolerated, but a higher percentage of treated dogs (17.02%) had occasional vomiting as compared to the placebo group (6.25%).    Conclusions and Clinical Importance  Grapiprant is an effective treatment for alleviation of pain in dogs with  OA , and represents a modality of treatment that may be better tolerated than current options.

journal of veterinary internal medicine

A Prospective, Randomized, Masked, Placebo‐Controlled Multisite Clinical Study of Grapiprant, an  EP 4 Prostaglandin Receptor Antagonist (PRA), in Dogs with Osteoarthritis